Curated primary research: novel 3D cardiac organoid systems

---

Papers were prioritised by: (i) publication date (2015-Present), venue impact and  selectivity; (ii) clear methodological novelty; (iii) explicit relevance  to 3D cardiac organoids or cardiac electrophysiology interfaces; and  (iv) availability of unambiguous DOI and methods/functional readouts in  primary sources.

Reference: Lika Drakhlis et al. Human heart-forming organoids recapitulate early heart and foregut development. Nature Biotechnology (2021).  DOI: 10.1038/s41587-021-00815-9.

Novelty/technique: The study embeds human pluripotent stem cell aggregates in Matrigel and applies biphasic WNT modulation to generate complex, structured heart-forming organoids that co-develop myocardial and endocardial-like structures alongside foregut endoderm and vasculature. It explicitly targets early cardiogenesis coupled to neighbouring tissue interactions, rather than adult-like engineered myocardium.
Key methods: hPSCs aggregated and embedded in Matrigel;  directed cardiac differentiation via small-molecule WNT  activation/inhibition; readouts include tissue architecture and lineage  composition, vascular network evidence, and genetic perturbation  phenotyping (NKX2.5 knockout).
Main findings: HFOs show layered organisation  (myocardial, endocardial-like), additional tissue components  (septum-transversum-like, foregut endoderm) and a vascular network;  NKX2.5-knockout HFOs exhibit organoid phenotypes consistent with cardiac  malformations reported in vivo. 

Model type: In vitro human-derived organoids (with gene-editing perturbation). 

Journal impact factor: Nature Biotechnology 41.7.

Reference: Pablo Hofbauer et al. Cardioids reveal self-organizing principles of human cardiogenesis. Cell (2021). DOI: 10.1016/j.cell.2021.04.034.

Novelty/technique: Establishes self-organising cardioids from human pluripotent stem cells that form chamber-like cavities,  with tunable complexity by signalling control of  cardiomyocyte–endothelial layering and epicardial behaviours. It links  cavity morphogenesis to a mesodermal WNT–BMP axis and the transcription factor HAND1.
Key methods: hPSC-derived self-organisation; signalling  modulation to control layer separation and epicardial  spreading/migration; perturbation of WNT–BMP/HAND1; functional  injury-style perturbation via cryoinjury; readouts include cavity  formation, ECM accumulation, and lineage-layer organisation.
Main findings: Demonstrates controllable formation of  cavity-bearing cardioids; identifies a WNT–BMP–HAND1 pathway requirement  for cavity morphogenesis; cryoinjury triggers cell-type-dependent ECM  accumulation as an early regeneration/disease hallmark. 

Model type: In vitro human-derived organoids (with mechanistic pathway dissection).
Journal impact factor: Cell Impact Factor 42.5.

Reference: Yonatan Lewis-Israeli et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. Nature Communications (2021).

DOI: 10.1038/s41467-021-25329-5. 

Novelty/technique: Reports an efficient, defined approach to generate developmentally relevant human heart organoids by self-assembly, positioned as compatible with high-content analysis. The system is framed for studying congenital heart defects with multi-lineage structure and functional activity.
Key methods: Human pluripotent stem cell self-assembly  with defined factors; readouts include structural and developmental  modelling capacity and compatibility with high-content approaches;  (article-level methods and composition are described on the Nature  article page).
Main findings: Establishes a reproducible human heart  organoid method that models aspects of embryonic heart structure, early  patterning, and congenital malformations. 

Model type: In vitro human-derived organoids.
Journal impact factor: Nature Communications 15.7.

Reference: Caroline Meier et al. Epicardioid single-cell genomics uncovers principles of human epicardium biology in heart development and disease. Nature Biotechnology (2023).
DOI: 10.1038/s41587-023-01718-7. 

Novelty/technique: Generates self-organising epicardioids with retinoic acid-dependent patterning that resembles aspects of the left ventricular wall,  including a structured epicardial compartment alongside ventricular  myocardium. The paper combines lineage tracing and single-cell  transcriptomics/chromatin accessibility to link in vitro trajectories to  human fetal development and to interrogate multicellular disease  phenotypes.
Key methods: hPSC spheroid differentiation in 96‑well  plates with staged modulation of WNT/activin A/BMP4/bFGF with RA  exposure; embedding in type I collagen; optional VEGF to enhance  endothelial features; readouts include scRNA‑seq, chromatin  accessibility profiling, lineage tracing, immunostaining, and functional  disease-like phenotyping (hypertrophy/fibrosis).
Main findings: RA timing/dose creates reproducible  epicardial compartment formation; multiomics identifies lineage  specification trajectories and signals (e.g., IGF2/IGF1R, NRP2)  implicated in cardiogenesis; epicardioids reproduce multicellular  hypertrophy and fibrotic remodelling features under congenital or  stress-like conditions. 

Model type: In vitro human-derived organoids.
Journal impact factor: Nature Biotechnology 41.7.

Reference: Brett Volmert et al. A patterned human primitive heart organoid model generated by pluripotent stem cell self-organization. Nature Communications (2023).
DOI: 10.1038/s41467-023-43999-1. 

Novelty/technique: Introduces a self-organisation strategy incorporating metabolic and hormonal factors to mimic aspects of in utero gestation, aiming for higher anatomical  and physiological relevance. The organoids recapitulate features such as  large atrial/ventricular chambers, proepicardial organ formation, and retinoic-acid-mediated anterior–posterior patterning in a post‑heart‑tube stage.
Key methods: Human pluripotent stem cell-based organoid  induction with developmentally inspired maturation conditions; readouts  include morphological/transcriptional similarity to age‑matched  embryonic hearts and proof-of-concept developmental toxicity testing  with ondansetron. 

Main findings: Shows transcriptional and morphological  similarity to age-matched human embryonic hearts; enables interrogation  of developmental drug effects (ondansetron) on embryonic heart structure  and electrophysiology-associated outcomes. 

Model type: In vitro human-derived organoids.
Journal impact factor: Nature Communications 15.7.

Reference: Miriana Dardano et al. Blood-generating heart-forming organoids recapitulate co-development of the human haematopoietic system and the embryonic heart. Nature Cell Biology (2024). DOI: 10.1038/s41556-024-01526-4. 

Novelty/technique: Extends an HFO framework to produce blood-generating HFOs featuring haemogenic endothelium and haematopoietic derivatives  alongside a functional ventricular-like heart anlagen. The model aims to  capture tissue‑integrated haematopoiesis in a structured developmental  context that is otherwise constrained by limited embryo access.
Key methods: Matrigel-embedded hPSC aggregates with  biphasic WNT modulation as a base; protocol modulation to promote  haemogenic endothelium and haematopoietic progenitors; readouts include  structured co-development claims and functional potential of  haematopoietic derivatives (erythro‑myeloid and lymphoid).
Main findings: Blood-generating HFOs maintain  myocardial/ventricular-like organisation while adding a  mesenchyme‑embedded haemogenic endothelial layer and haematopoietic  progenitors reflecting aspects of primitive and definitive  haematopoiesis. 

Model type: In vitro human-derived organoids (cardiac + haemato-endothelial co-development).
Journal impact factor: Nature Cell Biology 19.1.

Reference: Minh Duc Pham et al. Human heart organoids reveal a regenerative strategy for mitochondrial disease. bioRxiv (2025). DOI: 10.64898/2025.12.18.695153.

Novelty/technique: The study establishes a multi-lineage, vascularised, perfused and innervated human 3D cardiac organoid platform to model mitochondrial cardiomyopathy and clonal mitochondrial dynamics in a structurally organised tissue context. Rather than focusing solely on engineered myocardium, the system incorporates multiple cardiac cell types and network formation to enable metabolic selection and functional rescue studies within a human-relevant 3D microenvironment.

Key methods: Human pluripotent stem cell–derived aggregates differentiated into complex cardiac organoids comprising cardiomyocytes and non-myocyte populations; disease modelling of mitochondrial dysfunction; pharmacological metabolic modulation; contractility measurements, mitochondrial functional assays, and molecular profiling to assess wild-type versus mutant mitochondrial selection.

Main findings: The organoids recapitulate key features of mitochondrial cardiac disease, including impaired contractile performance and bioenergetic dysfunction. Targeted metabolic modulation selectively enhances wild-type mitochondrial function, improves tissue-level contractility, and demonstrates a regenerative selection mechanism in a human 3D system.

Model type: In vitro human-derived multi-lineage cardiac organoids for disease modelling and therapeutic screening (cardiac NAM platform).

Reviews were selected using four filters: recency (≤12 years, ≤5 years weighted), platform relevance (cardiac organoids or cardiac NAM technologies), translational applicability (safety, efficacy, or regulatory context), and publication impact (peer-reviewed journals with established scientific reach). The objective was to represent distinct architectural classes and deployment contexts within the cardiac NAM ecosystem rather than to rank individual publications.

Reference: Kim, H. et al. Progress in multicellular human cardiac organoids for clinical applications. Cell Stem Cell (2022). DOI: 10.1016/j.stem.2022.03.012. 

This perspective reviews the major architectural classes of human cardiac organoids (including self-organizing and engineered approaches) and the engineering choices that determine tissue structure, maturation, and reproducibility. It also frames practical requirements for clinical and translational use (e.g., scalability, standardized readouts, and quality control).

Reference: Thomas, D. et al. Cellular and Engineered Organoids for Cardiovascular Models. Circulation Research (2022). DOI: 10.1161/CIRCRESAHA.122.320305. 

This review maps the cardiovascular “organoid spectrum,” spanning engineered tissues, organoids, and related microphysiological constructs, with emphasis on how design choices affect physiological fidelity. It’s particularly useful for clearly defining terminology (organoids vs engineered tissues vs MPS) and for linking platform architecture to the types of questions each system can credibly answer.

Reference: Zhu, L. et al. Cardiac Organoids: A 3D Technology for Modeling Heart Development and Disease. Stem Cell Reviews and Reports (2022). 

DOI: 10.1007/s12015-022-10385-1.

This review provides a comprehensive overview of cardiac organoid generation strategies using pluripotent stem cell–derived populations. It discusses structural organization, maturation challenges, and functional readouts while evaluating the advantages and current technical limitations of 3D cardiac systems. The article serves as a foundational reference for understanding organoid construction and translational potential.

Reference: Yaqinuddin, A. Cardiac Organoids: A New Tool for Disease Modeling and Drug Discovery. Cells (2025). DOI: 10.3390/cells15010007.

This review explores the expanding role of cardiac organoids in modeling cardiovascular disease and supporting pharmacological evaluation. It highlights emerging integration with microfluidic and organ-on-chip technologies to improve physiological fidelity. The article situates organoids within the broader landscape of translational in vitro platforms.

Reference: Ingber, D.E.  Human organs-on-chips for disease modelling, drug development and personalized medicine. Natu Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics (2022). 

DOI: 10.1038/s41576-022-00466-9. 

This widely cited review synthesizes how organs-on-chips/MPS are used for disease modeling, drug development decisions, and patient-relevant translation. While not cardiac-only, it provides the strongest “big picture” argument for NAM-based disease modeling workflows and can be used to frame cardiovascular NAMs as a leading application class.

Reference: Loewa, A. et al. Human disease models in drug development. Nature Reviews Bioengineering (2023). DOI: 10.1038/s44222-023-00063-3. 

This review discusses how modern human disease models (including advanced in vitro systems) are being positioned in drug development as translational infrastructure—supporting mechanism, target validation, and early clinical decision-making. It is especially useful for your “buyer journey” narrative because it frames where these models sit in the development funnel and what constitutes credible evidence.

Reference: Leung, C.M.  et al. A guide to the organ-on-a-chip. Nature Reviews Methods Primers (2022). DOI: 10.1038/s43586-022-00118-6. 

This primer is a high-authority reference on how organ-on-chip systems are constructed, validated, and operationalized—covering key translational considerations (e.g., exposure control, sensing endpoints, standardization). It’s a strong fit for your translational section because it supports credible language around “context-of-use,” reproducibility, and decision-grade reporting.

Reference: Xuan, W. et al. Transformational Applications of Human Cardiac Organoids in Disease Modeling, Drug Discovery, and Cardiotoxicity Screening. Frontiers in Cell and Developmental Biology (2022). DOI: 10.3389/fcell.2022.936084.

This review synthesizes evidence supporting the use of human cardiac organoids in disease modeling, cardiotoxicity assessment, and drug discovery. It examines how tissue-level responses may improve mechanistic insight and predictive capacity. The authors emphasize translational considerations and future clinical alignment.

Reference: Escopete, S. et al. Human Cardiac Organoids for Disease Modeling and Drug Screening: Advances and Challenges. Trends in Molecular Medicine(2025).
DOI: 10.1016/j.molmed.2025.08.004.

This article presents a structured framework linking organoid construction methods to disease phenotypes and therapeutic testing applications. It evaluates how 3D multicellular systems contribute to more physiologically relevant modeling of pathological processes. Practical implementation considerations and future development pathways are discussed.

Reference: Pierson, J.B. et al. Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development. ALTEX (2025). DOI: 10.14573/altex.2401231.

This review focuses specifically on validation strategies and context-of-use definitions for cardiac NAM platforms in safety pharmacology. It discusses how integrated endpoints can inform risk assessment and regulatory conversations. The article emphasizes reproducibility, mechanistic interpretability, and structured deployment in development workflows.

Reference: Matsui, T. et al. Human Organoids for Predictive Toxicology Research and Applications. Frontiers in Genetics (2021). DOI: 10.3389/fgene.2021.767621.

This review evaluates organoid systems across toxicology domains, including cardiac applications. It assesses how 3D human tissue models may improve predictive power relative to conventional assays. The authors highlight the importance of validation frameworks and integration into broader testing strategies.

Reference: Chen, M. et al. Human Cardiac Organoids: Advances and Prospects in Preclinical Drug Evaluation. Cells (2025). DOI: 10.3390/cells15010007.

This article reviews advances in organoid construction and their application in preclinical drug evaluation. It integrates disease modeling, functional readouts, and translational considerations within a single framework. The review outlines remaining challenges in maturation and standardization.

Reference: Van Norman, G.A. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? JACC: Basic to Translational Science (2019). DOI: 10.1016/j.jacbts.2019.10.008. 

This review critically examines why nonhuman animal studies often fail to predict human toxicity, highlighting biological species differences and limitations in translational validity. It sets up the rationale for greater use of human-relevant NAMs by arguing that current paradigms can generate false reassurance (or false risk) and contribute to costly late-stage failures.

Reference: Cook, D., Brown, D., Alexander, R. et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery (2014). DOI: 10.1038/nrd4309. 

This highly cited analysis proposes AstraZeneca’s “5R” framework (Right Target, Right Patient, Right Tissue, Right Safety, Right Commercial Potential) as a structured lens for improving R&D productivity and reducing late-stage attrition. It is often referenced in translational and regulatory strategy contexts because it frames development success as a function of fit-for-purpose evidence generation and decision quality. 

Reference: Gu, B. et al. Heart-on-a-Chip Systems with Tissue-Specific Functionalities for Physiological, Pathological, and Pharmacological Studies. Materials Today Bio (2024).
DOI: 10.1016/j.mtbio.2023.100914.

This review explores heart-on-chip technologies that incorporate perfusion, sensing, and engineered tissue architecture. It discusses how microfluidic control enables dynamic exposure and improved physiological modeling. The article positions MPS platforms as complementary tools within cardiac NAM strategies.

Reference: Vuorenpää, H. et al. Building Blocks of Microphysiological Systems to Model the Human Heart. Frontiers in Physiology (2023). DOI: 10.3389/fphys.2023.1213959.

This review analyzes the structural and biological components required to construct functional cardiac microphysiological systems. It covers cell sources, biomaterials, mechanical stimulation, and electrophysiological readouts. The authors emphasize modular design and reproducibility in translational applications.

These papers are frequently used as “bridge” models between self-organisation and monocultures.

Reference: Molly E. Kupfer et al. In situ expansion,  differentiation, and electromechanical coupling of human cardiac muscle  in a 3D bioprinted, chambered organoid. Circulation Research (2020). DOI: 10.1161/CIRCRESAHA.119.316155.
Novelty/technique: Uses hiPSC‑laden ECM bioink to 3D bioprint a two‑chamber structure; cells proliferate and then differentiate in situ to form contiguous muscle with action potential propagation and pump-like behaviours.
Key methods/readouts: Photo-crosslinkable ECM bioink; 3D print chamber  geometry; in situ differentiation; functional readouts include beating,  continuous AP propagation, pacing/drug responses, and pressure/volume  relationships enabled by connected chambers.
Model type: In vitro human-derived (engineered organoid-like).
Journal impact factor: Circulation Research 16.2.

Reference: Dylan J. Richards et al. Inspiration from heart development: Biomimetic development of functional human cardiac organoids. Biomaterials (2017). 

DOI: 10.1016/j.biomaterials.2017.07.021.
Novelty/technique: Defined mixture of cardiac cell types self-organises without flow into functional myocardium containing lumenised vascular network-like  structures, enabling heart disease and drug cardiotoxicity modelling.
Journal impact factor: Biomaterials Impact Factor 12.9.

Reference: Richard J. Mills et al. Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. PNAS (2017). DOI: 10.1073/pnas.1707316114.
Journal impact factor: PNAS Impact Factor 9.1.

Reference: Mills et al. Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. Cell Stem Cell (2019). DOI: 10.1016/j.stem.2019.03.009.
Journal impact factor: Cell Stem Cell Impact Factor 20.4.